HIF1A and cyclic hematopoiesis: It was found that pretreatment with the prolyl hydroxylase inhibitor dimethyloxalylglycine enhanced a CH-induced increase in the HIF-1α level in myocardial tissue, and attenuated RV hypertrophy and myocardial fibrosis, consequently, HIF-1α did not trigger RV hypertrophy in CH[81].